# Improved efficiency of the new Mirus™ system challenged by ventilatory settings—a bench study

**Authors:** Frederic Albrecht, Claudia Schirra, Kathrin Scheffler, Thomas Volk, Andreas Meiser

PMC · DOI: 10.1007/s10877-025-01344-5 · Journal of Clinical Monitoring and Computing · 2025-08-23

## TL;DR

A new system for delivering anesthesia was tested and found to be efficient but has limitations with high concentrations and short breathing cycles.

## Contribution

The study evaluates the performance of the new Mirus™ system under various ventilatory settings and identifies conditions that affect its efficiency.

## Key findings

- Mirus EC measurements correlated well with external gas monitor readings.
- Anaesthetic consumption was lower than historical controls and comparable to the Sedaconda ACD.
- Very short inspiratory flow times significantly increased consumption, especially at high concentrations.

## Abstract

The Mirus™ system (Technologie Institut Medizin GmbH, Germany) enables target-controlled delivery of volatile anaesthetics with open system ventilators. Its interface, positioned between Y-piece and the patient, injects anaesthetic vapor during inspiration, while adsorbing anaesthetic and resupplying it during the next inspiration. A newly introduced interface (Lisa-44) was evaluated under body temperature pressure saturated and normocapnic conditions using a test lung. Volume-controlled ventilation was applied with a 500 mL tidal volume, 10 bpm respiratory rate, and inspiratory flow (IF) times of 2.5 s and 0.5 s. Isoflurane (sevoflurane) target concentrations were stepwise increased to 1.5 MAC and then decreased. An external gas monitor recorded real-time anaesthetic concentrations. End-tidal concentrations (EC) and area under the curve (AUC) were analyzed for each breath. Accuracy and precision were assessed using Bland-Altman plots. Consumption was calculated and compared to historical controls. Mirus EC measurements correlated well with external gas monitor readings. ECs fluctuated around targets, with higher targets requiring more frequent injections and larger AUCs. Anaesthetic consumption was lower than historical controls and comparable to the Sedaconda ACD. At 0.3–0.5 MAC, hourly isoflurane consumption ranged from 1.0 to 1.7 mL (sevoflurane: 3.8–6.1 mL). However, very short IF times significantly increased consumption, reaching 43 mL sevoflurane at an EC of 2.6 vol%, with prolonged injections extending into the expiration phase. The new system demonstrates high accuracy, precision, and improved efficiency, suggesting reduced anaesthetic consumption in clinical use. However, high concentrations combined with very short IF times substantially increase consumption, indicating potential limitations.

## Linked entities

- **Chemicals:** isoflurane (PubChem CID 3763), sevoflurane (PubChem CID 5206)

## Full-text entities

- **Chemicals:** sevoflurane (MESH:D000077149), Isoflurane (MESH:D007530)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963147/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12963147/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12963147/full.md

---
Source: https://tomesphere.com/paper/PMC12963147